A Plus Biotechnology Co., Ltd. (TPE:6918)
Taiwan · Delayed Price · Currency is TWD 73.00
-0.10 (-0.14%)
At close: May 28, 2026
A Plus Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 858.89 | 835.89 | 769.59 | 675.05 | 541.85 | 503.29 | |
Revenue Growth (YoY) | 8.99% | 8.62% | 14.01% | 24.58% | 7.66% | - |
Cost of Revenue | 280.96 | 262.43 | 234.81 | 214.37 | 195.46 | 185.36 |
Gross Profit | 577.93 | 573.46 | 534.78 | 460.67 | 346.39 | 317.93 |
Selling, General & Admin | 322.93 | 318.06 | 299.15 | 233.43 | 237.16 | 203.12 |
Research & Development | 46.7 | 46.64 | 53.34 | 59.54 | 63.08 | 79.96 |
Operating Expenses | 369.62 | 364.7 | 352.32 | 293.13 | 299.65 | 275.4 |
Operating Income | 208.31 | 208.76 | 182.46 | 167.54 | 46.74 | 42.53 |
Interest Expense | -2.16 | -2.17 | -2.19 | -2.69 | -2.2 | -1.19 |
Interest & Investment Income | 3.65 | 3.79 | 2.27 | 1.71 | 0.42 | 2.05 |
Earnings From Equity Investments | 8.11 | 3.66 | - | - | - | - |
Currency Exchange Gain (Loss) | 1.6 | 1.6 | 1.68 | 0.03 | - | - |
Other Non Operating Income (Expenses) | 1.76 | 0.47 | 3.35 | -163.59 | 1.1 | 4.36 |
EBT Excluding Unusual Items | 221.26 | 216.12 | 187.57 | 3 | 46.06 | 47.75 |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.01 | - | - | - |
Other Unusual Items | 0.02 | 0.02 | - | 0.04 | - | - |
Pretax Income | 221.28 | 216.14 | 187.56 | 3.04 | 46.06 | 47.75 |
Income Tax Expense | 47.68 | 46.6 | 36.5 | 14.34 | 10.43 | 8.71 |
Earnings From Continuing Operations | 173.61 | 169.54 | 151.06 | -11.31 | 35.63 | 39.04 |
Minority Interest in Earnings | -0.35 | -0.16 | - | - | -2.69 | -2.97 |
Net Income | 173.26 | 169.38 | 151.06 | -11.31 | 32.94 | 36.06 |
Net Income to Common | 173.26 | 169.38 | 151.06 | -11.31 | 32.94 | 36.06 |
Net Income Growth | 9.09% | 12.13% | - | - | -8.66% | - |
Shares Outstanding (Basic) | 34 | 33 | 30 | 30 | 29 | 29 |
Shares Outstanding (Diluted) | 34 | 33 | 30 | 30 | 29 | 29 |
Shares Change (YoY) | 11.14% | 8.36% | 0.37% | 4.70% | 0.95% | - |
EPS (Basic) | 5.14 | 5.16 | 4.99 | -0.37 | 1.15 | 1.26 |
EPS (Diluted) | 5.13 | 5.15 | 4.97 | -0.37 | 1.14 | 1.26 |
EPS Growth | -1.63% | 3.62% | - | - | -9.52% | - |
Free Cash Flow | 22.18 | 144.79 | 152.09 | 149.72 | -168.55 | 107.35 |
Free Cash Flow Per Share | 0.66 | 4.40 | 5.01 | 4.95 | -5.83 | 3.75 |
Dividend Per Share | 5.000 | 5.000 | 4.000 | 2.700 | - | - |
Dividend Growth | 25.00% | 25.00% | 48.15% | - | - | - |
Gross Margin | 67.29% | 68.60% | 69.49% | 68.24% | 63.93% | 63.17% |
Operating Margin | 24.25% | 24.98% | 23.71% | 24.82% | 8.63% | 8.45% |
Profit Margin | 20.17% | 20.26% | 19.63% | -1.68% | 6.08% | 7.17% |
Free Cash Flow Margin | 2.58% | 17.32% | 19.76% | 22.18% | -31.11% | 21.33% |
EBITDA | 225.26 | 224.9 | 197.32 | 181.35 | 68.17 | 68.01 |
EBITDA Margin | 26.23% | 26.91% | 25.64% | 26.86% | 12.58% | 13.51% |
D&A For EBITDA | 16.95 | 16.14 | 14.86 | 13.81 | 21.43 | 25.48 |
EBIT | 208.31 | 208.76 | 182.46 | 167.54 | 46.74 | 42.53 |
EBIT Margin | 24.25% | 24.98% | 23.71% | 24.82% | 8.63% | 8.45% |
Effective Tax Rate | 21.55% | 21.56% | 19.46% | 472.12% | 22.64% | 18.24% |